Company: NYXH
Filing Date: 2025-03-20
Form Type: 20-F
Source: 0001410578-25-000398
Chunk: 17

Company: Nyxoah SA
Filing Date: 2025-03-20
Form: 20-F
Item: Item 5
Chunk 17
---
 used in investing activities of €90.0 million in 2022. The change of €122.0 million compared to 2022 is mainly due to the fact that during 2022 purchases of term accounts amounted to €102.6 million offset by €28.9 million term accounts reaching their maturity (after which the term deposit is held as cash), whereas in 2023, purchases of term accounts amounted to €80 million, offset by €120.7 million in term accounts reaching their maturity.
Financing activities. Net cash from financing activities in 2023, was €16.9 million compared to net cash used in financing activities of €1.0 million in 2022. The increase was primarily derived from several capital increases during 2023. See Note 15 to our consolidated financial statements found elsewhere in this Annual Report.
Operating and Capital Expenditure Requirements
We use our cash to fund our operations, which primarily include the cost of manufacturing our Genio system, as well operating expenses and related personnel costs. We expect research and development expenses to increase for the foreseeable future as we continue to hire personnel and invest in next-generation innovations of the Genio system and related products. In addition, we expect our general and administrative expenses to increase for the foreseeable future as we hire personnel and expand our infrastructure to both drive and support the anticipated growth in our organization. We will also incur additional expenses as a result of operating as a dual listed public company and also expect to increase the size of our administrative function to support the growth of our business. The timing and amount of our operating expenditures will depend on many factors, including:

●   acceptance of our therapy by patients, physicians, government payers, private payers, and the market generally;
-------------------------------------------------------------------------------------------------------------------

●   the scope, rate of progress and cost of current or future clinical studies;
-------------------------------------------------------------------------------

●   the cost of research and development activities;
----------------------------------------------------

●   the cost associated with any complications or side effects related to the use of the Genio system;
------------------------------------------------------------------------------------------------------

●   the cost of filing and prosecuting patent applications and other intellectual property rights and defending and enforcing our patents or other intellectual property rights in various jurisdictions;
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

●   the cost of defending, in litigation or otherwise, any claims that we infringe third-party patents or other intellectual property rights;
---------------------------------------------------------------------------------------------------------------------------------------------

●   the cost and timing of additional regulatory clearances or approvals;
-------------------------------------------------------------------------

●   the cost and timing of establishing additional sales and marketing capabilities;
------------------------------------------------------------------------------------

●   costs associated